Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MINE+X in R/R DLBCL
NCT05784987Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators
01
Overview
Open-label trial of mitoxantrone, orelabrutinib, tucidinostat, penpulimab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
mitoxantroneorelabrutinibtucidinostatpenpulimablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05784987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784987.